COVID-19 Urgent Public Health Research Response in NWC LCRN

Gerry Davies

Infectious Diseases Specialty Lead

(on behalf of Andrea Collins, Hassan Burhan, Ingeborg Welters, David Lewis, Stacy Todd)

NIHR | Clinical Research Network North West Coast

Challenge

NIHR | Clinical Research Network North West Coast

Nations | Regions | UTLA | LTLA

Region	Total cases	Rate
East Midlands	22,742	473.4
East of England	24,271	391.4
London	34,695	389.5
North East	15,246	573.6
North West	44,539	610.8
South East	34,789	380.9
South West	12,991	232.0
West Midlands	26,390	447.2
Yorkshire and The Humber	30,991	565.6

Rate | Total cases

Rates per 100,000 resident population. Darker shades have higher rates.

Challenge

NIHR | Clinical Research Network North West Coast



RECOVERY
Randomised Evaluation of COVID-19 Therapy

REMAP-CAP

PRIEST

ISARIC 4C
Coronavirus Clinical Characterisation Consortium

COVID-19
Oxford Vaccine Trial

ACCORD
ACcelerating COVID-19 Research and Development

Challenge

NIHR | Clinical Research Network North West Coast

NWC Portfolio Impact July 2020



Response

NIHR | Clinical Research Network North West Coast

- UPH Working group convened by NW LCRN
- Specialty leads and co-opted representatives of sites and CRFs
- Research and data managers
- Review of impact and conflicts, recommendations to sites
- Monitoring of EoIs and escalation of national contacts

Response

NIHR | Clinical Research Network North West Coast



Urgent Public Health Studies Tracker

File Edit View Insert Format Data Tools Add-ons Help Last edit was made 4 days ago by Karen Lomax

Share

Study RAG rating

Study RAG rating	Date Added	Study acronym / short title	Study title	Chief Investigator (Institution)	Funder	Commercial / Non Commercial	Sponsor	Lead LCRN	IRAS Number	CPMS ID	Potential managing Specialty	Study Summary	Assigned SMT	Assigned PRF	CRN NWC Resources	EOI/Scop
[redacted]	01/04/2020	ACTT-EU.UK	A Multicentre, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalised Adults a Version for European Union/United Kingdom sites	Professor Sarah L Pett			University of Minnesota (through UCL)		281800	45521		This study is an adaptive, randomised, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. The study is a multicentre trial that will be conducted in up to approximately 75 sites globally. The study will compare different investigational therapeutic agents to a control arm. There will be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). Any such				
Key UPH commercial trial with strong rationale NWC sites not selected	03/04/2020	SNG001	A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNB-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection	Professor Tom Wilkinson	Synairgen Research Limited	Commercial	Synairgen Research Limited	Wessex	281317	45382	Respiratory Disorders	The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of LRT illness in the context of SARS-CoV-2. Safety and efficacy will be assessed.	Gavin Soady	James Connolly Carol Stanton		Sponsor u identify as process w Liverpool
Scientifically novel. Only feasible in sites with stem cell capabilities	02/04/2020	REALIST	Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST)	Professor Danny McAuley	Wellcome Trust	Non Commercial	Belfast Health and Social Care Trust		227090	40531	Respiratory Disorders	The Primary objective is to assess the safety of a single intravenous infusion of MSCs in patients with ARDS due to COVID-19 Secondary objective are to determine the effects of MSCs on: Physiological indices of respiratory dysfunction reflecting severity of ARDS, as measured by oxygenation index (OI), respiratory compliance, and P/F ratio	Simon Dyas	Laura Dawson		07/04/202 additional 08/04/202 addition
Key diagnostic/prognostic study Liverpool scientific partner. Co-enrolment possible Likely limited to Aintree, Key and LUHFT by sponsor	03/04/2020	DIAMONDS	Diagnosis and Management of Febrile Illness using DNA Personalised Molecular Signature Diagnosis (DIAMONDS)	Michael Levin	European Commission	Non Commercial	Imperial College London	North West London	278651	45537	Children	A five year project that seeks to improve diagnosis of infectious and inflammatory illness in patients of all ages, through development of diagnostic tests based on host gene expression responses. The DIAMONDS project follows on from the H2020-funded PERFORM study, which is in its final year (also co-ordinated in the UK by Imperial College) In the first part of the study (DIAMONDS Search), the consortium - which includes multiple UK centres as well as 14 international partners - will carry out an observational study recruiting children and adults to generate a biobank of samples with a range of infectious and inflammatory conditions from which diagnostic gene expression signatures will be deduced.	Kirsty Pine	Kerry Gibbons		Multi Site IRAS sub NWC site
Case-based study w/ [redacted]	03/04/2020	[redacted]	Coronavirus infection in primary or secondary immunosuppressed children	Dr Hans de Graff	British Paediatric Allergy, Immunity and Infection Group	Non Commercial	University of Southampton NHS Foundation Trust	Wessex	281544	45332	Children	The study is designed to allow families of immunosuppressed children and young people to self-record their experiences of COVID-19 and other viral respiratory illnesses during the COVID-19 epidemic. Parents of immunosuppressed patients and young people aged16-17 yrs who are immunosuppressed will be provided with online information and asked to fill in online questionnaires at baseline and weekly thereafter. Information collected will include immune-system affecting medication, symptoms, contact with health care providers, test results and impact on daily activities. Data will be	Kirsty Pine	Kerry Gibbons		Recruiting of PIC site

Summary | National UPH Studies | UPH Sites | UPH NWC PIVOT (PC) | NWC Capacity & Capability | NWC Site Capabilities | Explore

Performance

NIHR | Clinical Research Network North West Coast

24	2	20	13	7,700
studies on CRN Portfolio	studies in setup	studies open to recruitment	studies have recruited	participants have been recruited



Successes

NIHR | Clinical Research Network North West Coast



COVID-19
Oxford Vaccine Trial



Lessons

NIHR | Clinical Research Network North West Coast

- NW Coast CRN performance unprecedented
- Set-up and recruitment capability nationally competitive
- Locally co-ordinated approach critical to delivery
- Successful models of local partnership (HCW platform, 3 CRUs, vaccine hubs)
- Expand pool of CIs and PIs
- Strengthen support for CTIMP trials

Looking ahead

NIHR | Clinical Research Network North West Coast

Daily number of lab-confirmed cases in England by specimen date



Total confirmed cases showing those previously reported and newly added cases separately. New cases are attributed to the day the specimen was taken.

Looking ahead

NIHR | Clinical Research Network North West Coast

Summary

NIHR | Clinical Research Network North West Coast

- NW CRN response to COVID-19 was pro-active and successful
- Pandemic strengthened pre-existing mechanisms of partnership
- Notable improvements in research set-up and delivery
- Build on collaborative response under “peace-time” conditions
- Balance vaccine and non-COVID19 portfolio in short-term
- Promote locally relevant and led research